🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

Cases of gonorrhoea are on the rise globally, with figures suggesting more than 82 million instances each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, the spread of superbugs and the highly restricted available drugs at this time.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring revealed that resistance to standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Results and Worldwide Availability

Based on data released by a major medical journal, the new drug cured more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which involves an injection and a pill. The study enrolled over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, the non-profit has the authority to license and sell the drug in many developing nations.

Clinicians treating patients have shared optimism. Having a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is considered vital to alleviate the strain of the infection for people and to halt the transmission of extremely resistant gonorrhoea globally.